Fosinopril is an angiotensin-converting enzyme (ACE) inhibitor used as an active pharmaceutical ingredient in medicines for the treatment of hypertension and heart failure. It is a prodrug that is hydrolyzed in the body to form the active metabolite fosinoprilat, which inhibits ACE and reduces the formation of angiotensin II.
Fosinopril API is a cardiovascular pharmaceutical ingredient belonging to the ACE inhibitor class. It is used in pharmaceutical formulations for blood-pressure management and cardiovascular therapy. Fosinopril is commonly supplied as fosinopril sodium, the sodium salt used in finished pharmaceutical products.
CAS Number: 98048-97-6
Fosinopril Sodium CAS Number: 88889-14-9
Molecular Formula: C30H46N2O7P
Molecular Weight: 563.69 g/mol
Active Metabolite: Fosinoprilat
Drug Class: ACE Inhibitor
Therapeutic Class: Antihypertensive / Cardiovascular Agent
Fosinopril is a prodrug that is converted to fosinoprilat, its active diacid metabolite. Fosinoprilat inhibits angiotensin-converting enzyme, reducing the conversion of angiotensin I to angiotensin II. Reduced angiotensin II activity decreases vasoconstriction and aldosterone secretion, contributing to reduced blood pressure and decreased cardiac workload.
Fosinopril is used in pharmaceutical formulations for the treatment of hypertension and heart failure. It may be administered alone or in combination with other medicines according to the therapeutic regimen.
Fosinopril Sodium is the sodium salt of fosinopril and is the form commonly used in pharmaceutical products. It is available for oral administration and is formulated as tablets.
Fosinopril is a phosphinic-acid-containing ACE inhibitor prodrug. Its molecular structure contains phosphorus, nitrogen and multiple oxygen-containing functional groups. The compound is characterized by a molecular weight of approximately 563.69 g/mol.
Fosinopril API quality evaluation may include identification, assay, related substances, water content, residual solvents, residue on ignition, elemental impurities and other applicable pharmaceutical quality-control tests. HPLC and other validated analytical techniques can be used for assay and impurity determination.
Fosinopril should be stored in a tightly closed container under controlled pharmaceutical storage conditions and protected from excessive heat, moisture and direct light. Specific storage requirements should follow the applicable certificate of analysis and stability data.
Fosinopril is relevant to cardiovascular pharmacology because ACE inhibition affects the renin-angiotensin-aldosterone system. Its active metabolite, fosinoprilat, inhibits ACE and consequently reduces angiotensin II-mediated cardiovascular effects.
Fosinopril is an ACE inhibitor prodrug identified by CAS Number 98048-97-6 and molecular formula C30H46N2O7P. It is converted to fosinoprilat after administration and is used in pharmaceutical formulations for hypertension and heart failure.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.2% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 2.5 – 4.5 |
| Individual Impurity | ≤0.5% |
| Total Impurities | ≤2.0% |
| Melting Point | 150–160°C |